(firstQuint)A Phase I Study of TAS-102 in Solid Tumors.

 This is an open-label, non-randomized, single group Phase 1 study of TAS-102, evaluating the pharmacokinetics, safety, and antitumor activity.

 Blood sampling will be performed during the first cycle (Day1 and Day 12) of therapy in all consenting patients.

.

 A Phase I Study of TAS-102 in Solid Tumors@highlight

The primary objective of this study is to evaluate the pharmacokinetics of TAS-102 after single and multiple dose in Chinese patients with solid tumor.

